US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALPS Medical Breakthroughs ETF

56.15

-0.4900-0.87%

Post-market: 56.150.00000.00%19:30 EDT

Volume:59.46K

Turnover:3.36M

Market Cap:203.54M

PE:- -

High:57.37

Open:57.37

Low:55.93

Close:56.64

52wk High:70.85

52wk Low:39.40

Shares:3.63M

Float Shares:3.63M

Volume Ratio:1.87

T/O Rate:1.64%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26

Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million

Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million

THOMSON REUTERS

Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029

THOMSON REUTERS

Xenon Reports Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS

CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs

CG Oncology Q2 Net Loss Widens on Higher R&D Costs

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS

CG Oncology Q2 EPS USD -0.9

THOMSON REUTERS

CG Oncology Inc - Files for Offering of up to $500 Mln Common Stock - SEC Filing

THOMSON REUTERS

Market Chatter: AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

MT Newswires Live

Abbvie Seeks at Least $8 Billion in Debt to Fund Apogee Deal - Bloomberg News

THOMSON REUTERS

Abbvie : Plans to Use Note Offering Proceeds for Apogee Therapeutics Acquisition Funding

THOMSON REUTERS

Street View: Strength in AbbVie's Immunology Pipeline to Support Revenue Growth

Xenon Pharma Grants 32,758 Inducement Stock Options, 19,013 RSUs to New Hires

Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/SBIO/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":56.15,"timestamp":1790971200000,"preClose":56.64,"halted":0,"volume":59461,"hourTrading":{"tag":"盘后","latestPrice":56.15,"preClose":56.15,"latestTime":"19:30 EDT","volume":75,"amount":4095.0633,"timestamp":1790983804718,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00865112994350286,"floatShares":3625000,"shares":3625000,"eps":0,"marketStatus":"Market Closed","change":-0.49,"latestTime":"10-02 16:00:00 EDT","open":57.37,"high":57.37,"low":55.925,"amount":3364430.983306,"amplitude":0.025512,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":56.64,"sharesOutstanding":2675000,"nav":56.22,"aum":198187245.53,"bidAskSpread":0.002427,"postHourTrading":{"tag":"盘后","latestPrice":56.15,"preClose":56.15,"latestTime":"19:30 EDT","volume":75,"amount":4095.0633,"timestamp":1790983804718,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.8675640977225254,"impliedVol":0.2697,"impliedVolPercentile":0.8486},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3625000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8675640977225254,"shares":3625000,"dividePrice":0,"high":57.37,"amplitude":0.025512,"preClose":56.64,"low":55.925,"week52Low":39.4,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":56.15,"eps":0,"divideRate":0,"volume":59461,"delay":0,"ttmEps":0,"open":57.37,"prevYearClose":51.22,"prevWeekClose":57.56,"prevMonthClose":58.3,"prevQuarterClose":58.3,"fiveDayClose":57.56,"twentyDayClose":67.31,"sixtyDayClose":68.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657650667","title":"Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650667","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650667?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:16","pubTimestamp":1786047402,"startTime":"0","endTime":"0","summary":"Biopharma firm IN8bio's Q2 net loss narrows as expenses declineOverviewUS biopharma firm's Q2 net loss narrowed yr/yr, with flat R&D and lower G&A expensesCompany reported updated clinical data showin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","SBIO","BK4139","CGON","INAB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0009355771.USD","IMRX","LU0109394709.USD","GHRS","LU2065171402.SGD","LU0320765992.SGD","LU2065169927.USD","BK4539","IE00B2B36J28.USD","BK4563","IE00BJJMRZ35.SGD","LU0154245673.USD","NBIX","LU0823416689.USD","IE0002141913.USD","IBRN","BK4007","BK4139","LU0154245756.USD","PSIL","LU2065171311.SGD","SBIO","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","PRAX","IE00BJT1NW94.SGD","XENE","LU2324357040.USD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571056","title":"Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571056","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571056?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:07","pubTimestamp":1786046831,"startTime":"0","endTime":"0","summary":"Xenon net loss widens 30.7% to $110.74 million in Q2 FY26Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.R&D costs rose to USD 99.2 million from USD 75 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbgCR29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4112","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014013.SGD","SBIO","LU0314104364.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014039.USD","BK4139","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4588","SG9999014005.SGD","BCDF","LU2210149790.SGD","LU2210150020.SGD","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365271","title":"Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365271","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365271?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 MillionAug 06 (Reuters) - Xenon Pharmaceuticals Q2 income from operations USD -123.155 million.Q2 operating expenses USD 123.155 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4139","IBRN","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652480","title":"Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652480?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","BK4139","IBRN","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521606","title":"Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521606?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SBIO","XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657465223","title":"Xenon Reports Q2 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657465223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657465223?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA4YCGCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","XENE","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763093","title":"CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763093","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763093?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:21","pubTimestamp":1786026089,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. reports results for the quarter ended June 30 - Earnings SummaryCG Oncology, Inc.CGON.OQreported a quarterly adjusted loss of 90 cents per share for the quarter ended June 30, lower ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44329Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657263440","title":"CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657263440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657263440?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:04","pubTimestamp":1786021455,"startTime":"0","endTime":"0","summary":"CG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programsCG Oncology highlighted Phase 3 BOND-003 Cohort C in high-risk BCG-unresponsive CIS, reporting 76% compl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8wxmhj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4139","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657063925","title":"CG Oncology Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657063925","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657063925?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:22","pubTimestamp":1786018956,"startTime":"0","endTime":"0","summary":"CG Oncology Q2 net loss widens on higher R&D costsOverviewUS biopharmaceutical firm's Q2 rev rose to $1.2 mln, reflecting early commercialization activityNet loss widened to $79.1 mln, driven by highe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","SBIO","AVTX","BK4139","CGON","CHRS","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639609","title":"CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639609?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:15","pubTimestamp":1786018501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA70KC8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SBIO","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657396066","title":"CG Oncology Q2 EPS USD -0.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2657396066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657396066?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:15","pubTimestamp":1786018500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHMKD13:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657263613","title":"CG Oncology Inc - Files for Offering of up to $500 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657263613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657263613?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:02","pubTimestamp":1786017778,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4430WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","CGON","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633115","title":"Market Chatter: AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633115","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633115?lang=en_us&edition=fundamental","pubTime":"2026-08-05 01:40","pubTimestamp":1785865235,"startTime":"0","endTime":"0","summary":"AbbVie  has commenced a $10 billion investment-grade bond sale to help finance its pending acquisition of Apogee Therapeutics , Bloomberg reported Tuesday, citing people with direct knowledge of the matter.The offering, which includes bonds maturing in two to 40 years, has drawn about $63 billion of peak demand, the report said, citing the people.AbbVie didn't immediately reply to a request for comment from MT Newswires.Price: 243.24, Change: -1.86, Percent Change: -0.76","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["US10Y.BOND","AGNG","MEDX","FTXH","US30Y.BOND","LU1037948541.HKD","LU0511384066.AUD","TRUH","LU1162221912.USD","VHT","ABBV","LU2347655073.USD","LU0395794307.EUR","SBIO","LU0211328371.USD","LU0203345920.USD","LU0859254822.USD","FHLC","TLT","US3Y.BOND","IE00BVYPNV92.GBP","LU0912757837.SGD","LU1551013342.USD","RXL","TMF","LU1267930490.SGD","LU1585245621.USD","APGE","IXJ","XLV","TLTW","US5Y.BOND","US6M.BOND","JDOC","GLAM","US12M.BOND","IYH","US7Y.BOND","PJP","LU1093756168.USD","LU1923622614.USD","PPH","LU0943347566.SGD","US2Y.BOND","LU1244550221.USD","LU1934455863.HKD","LU0738911758.USD","IE00BJJMRZ35.SGD","LU0310799852.SGD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656590975","title":"Abbvie Seeks at Least $8 Billion in Debt to Fund Apogee Deal - Bloomberg News","url":"https://stock-news.laohu8.com/highlight/detail?id=2656590975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656590975?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:17","pubTimestamp":1785849448,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4410VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1551013342.USD","LU1093756325.SGD","SG9999003800.SGD","LU0965508806.USD","LU2089284900.SGD","AGNG","PPH","RXL","GLAM","LU0029864427.USD","LU2468319806.SGD","LU0053671581.USD","LU0058720904.USD","LU1551013425.SGD","IE00BFTCPJ56.SGD","ABBV","LU0861579265.USD","IE00BVYPNW00.USD","LU0211328371.USD","LU1244550494.USD","IYH","TRUH","MEDX","LU0726765562.USD","LU0661504455.SGD","FHLC","IXJ","VHT","LU2237443622.USD","LU0203347892.USD","PJP","XLV","LU0289961442.SGD","IE00BDGV0183.EUR","APGE","SBIO","JDOC","LU2125909593.SGD","LU1670628061.USD","LU2357627491.SGD","LU0289739343.SGD","LU0820561909.HKD","SG9999015952.SGD","LU0198837287.USD","LU1989771016.USD","IE00B42XCP33.USD","IE000MB6IJN5.SGD","LU2433249047.HKD","FTXH","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656550225","title":"Abbvie : Plans to Use Note Offering Proceeds for Apogee Therapeutics Acquisition Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2656550225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656550225?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:20","pubTimestamp":1785846049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4411E4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0795875169.SGD","MEDX","IE00BVYPNV92.GBP","LU1023059063.AUD","IE00BGHQF631.EUR","LU2089284900.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE000F7OJYX1.SGD","LU1074936037.SGD","IYH","LU1037948541.HKD","LU0320765646.SGD","FTXH","LU0868494617.USD","LU2112291526.USD","FHLC","LU1291159041.SGD","LU0211327993.USD","LU1057294990.SGD","IE00B42XCP33.USD","SBIO","PJP","JDOC","LU0395794307.EUR","LU1732799900.SGD","LU1718418525.SGD","ABBV","LU2125909593.SGD","XLV","LU1934455277.USD","APGE","TRUH","LU2023251221.USD","RXL","SG9999011175.SGD","GLAM","LU1934455194.USD","LU0289739343.SGD","LU1585245621.USD","LU2089984988.USD","VHT","AGNG","IXJ","LU1244550577.SGD","LU0708994859.HKD","PPH","LU0726765562.USD","LU2237443895.HKD","LU0198837287.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656837519","title":"Street View: Strength in AbbVie's Immunology Pipeline to Support Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2656837519","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656837519?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:32","pubTimestamp":1785756728,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Strength in AbbVie's immunology pipeline to support revenue growth** AbbVieABBV.Nslightly trimmed its 2026profit forecaston Friday to account for its planned Apogee Therapeutics acqu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4N4400Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","JDOC","LU0965509283.SGD","TRUH","GLAM","IE00B2B36J28.USD","LU1551013425.SGD","IE0002270589.USD","LU0912757837.SGD","LU0256863811.USD","LU1061106388.HKD","APGE","IE00BLSP4239.USD","IXJ","AGNG","IE000BZT7R73.USD","IE00BVYPNW00.USD","LU2468319806.SGD","LU1496350171.SGD","PJP","ABBV","IYH","LU1934455194.USD","LU0738911758.USD","RXL","VHT","LU0053671581.USD","IE00B42XCP33.USD","LU0861579265.USD","LU2433249047.HKD","SBIO","LU0170899867.USD","PPH","LU1003077747.HKD","BK4550","LU0689626769.HKD","LU2237443622.USD","IE000WAW04H5.SGD","LU0689472784.USD","IE00BVYPNV92.GBP","LU0820561909.HKD","LU2087621335.USD","IE00BBT3K403.USD","LU0289739699.SGD","FTXH","XLV","LU1934455863.HKD","LU0545039389.USD","LU1732800096.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656585399","title":"Xenon Pharma Grants 32,758 Inducement Stock Options, 19,013 RSUs to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656585399?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528080,"startTime":"0","endTime":"0","summary":"Xenon Pharma grants 32,758 inducement stock options, 19,013 RSUs to new hiresXenon Pharmaceuticals granted inducement equity awards to 11 new non-officer employees, totaling 32,758 share options and 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDLbfcL3N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","SBIO","IBRN","BK4139","IE00BN0W2V16.EUR","BK4588","NDAQ","XENE","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BCDF","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399370","title":"Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399370?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUA7BSC6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391209","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391209?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528060,"startTime":"0","endTime":"0","summary":"VANCOUVER, BC and BOSTON, MA, July  31, 2026  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical deve","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/31/3337042/33485/en/Xenon-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","XENE","LCLG","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":121,"code":"91000000","status":"200"}]}}